| 1 |
31594690 | GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). | 2020 Mar |
1 |
| 2 |
32734574 | Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor. | 2020 Dec |
2 |
| 3 |
29572333 | Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016. | 2018 Jun |
1 |
| 4 |
27821435 | What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015. | 2017 Jan |
1 |
| 5 |
28846049 | The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis. | 2017 Nov |
1 |